No Data
No Data
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
Best Quarterly Results in Company's History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing Authorization of Trunerox in Colombia
CBD Helps With This Rare Blistering Skin Disorder, New Study From Avicanna Shows Promising Results In Epidermolysis Bullosa Treatment
There is no cure for a rare blistering skin disorder called Epidermolysis Bullosa (EB), but treatments to help alleviate and control the symptoms do exist. The growing body of research suggests canna
Avicanna Announces Results of Study in Patients With Epidermolysis Bullosa
The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch.55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound stability. TORONTO, May 13,
Avicanna Announces Closing of Non-brokered Private Placement
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the completion of its observational real-world evidence ("RWE") study using RHO Phyto branded cannabigerol ("CBG") transdermal gel on patients with musculoskeletal pain and inflammation.
Earnings Call Summary | AVICANNA INC(AVCNF.US) Q4 2023 Earnings Conference
The following is a summary of the Avicanna Inc. (AVCNF) Q4 2023 Earnings Call Transcript:Financial Performance:Avicanna reported total revenue of $16.8 million for 2023, a 314% growth from the previou
No Data